Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).
Saved in:
| Title: | Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003). |
|---|---|
| Authors: | Kim JS; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Blood Cancer Research Institute, Seoul, Republic of Korea., Song Y; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Jen WY; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Chim CS; Comprehensive Oncology Centre, 3/F, Li Shu Fan Block, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China., Lee JJ; Chonnam National University Hwasun Hospital, Hwasun, Republic of South Korea., Yoon SS; Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea., Ng SC; Subang Jaya Medical Center, Petaling Jaya, Malaysia., Gan GG; Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia., Handa H; Department of Hematology, Gunma University Hospital, Maebashi, Gunma, Japan., Lee JH; Gachon University Gil Medical Center, Incheon, Republic of South Korea., Kim K; Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Republic of South Korea., Ito S; Department of Hematology & Oncology, Iwate Medical University Hospital, Yahaba, Japan., Huang JS; National Taiwan University, Taipei, Taiwan., Min CK; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Ooi Gaik Ming M; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., de Mel S; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Soekojo C; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Li X; Singapore Clinical Research Institute, Singapore, Singapore., Awasthi N; Singapore Clinical Research Institute, Singapore, Singapore., Pokharkar Y; Singapore Clinical Research Institute, Singapore, Singapore., Durie BG; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA., Chng WJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Oct 06; Vol. 15 (1), pp. 155. Date of Electronic Publication: 2025 Oct 06. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01356-z |
